Thomas Simmerer takes over sales at Carl Zeiss Meditec
Succeeds Ulrich Krauss as member of the management board with responsibility for sales
‘I am looking forward to my new responsibilities and will maintain and expand the successful sales and service structure at Carl Zeiss Meditec in the respective markets,’ said Simmerer.
Simmerer has extensive experience in medical technology. He was in charge of the Microsurgery strategic business unit in Oberkochen from October 2008. Before joining the medical wing of Carl Zeiss, the mechanical engineer led the top-performing business unit, among others, of Dräger Medical in Lübeck from 1996 to 2008. Prior to this, he was responsible for different sales areas at Heraeus in Hanau.
You may also like
Pharma 5.0
ZEISS and Concept Life Sciences partner to advance automated workflows and AI-powered image analysis in spatial biology
The collaboration focusses on high-throughput imaging, AI-driven data analysis and streamlined integration into lab systems, aiming to improve efficiency and data quality for areas such as drug discovery and cancer research
Research & Development
Medicines Discovery Catapult and ZEISS set sights on advancing microscopy in drug discovery
Medicines Discovery Catapult (MDC) and ZEISS have joined forces to improve drug discovery and early development of complex medicines by harnessing the power of advanced microscopy solutions
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Manufacturing
What makes a GMP quality system effective in day-to-day pharmaceutical manufacturing?
Your quality system may have a procedure for almost everything: reporting a deviation, reviewing a batch record, changing equipment settings and training the people who operate it. But having a procedure and getting a useful answer from it are two different things
Regulatory
Pheno Therapeutics secures two patents for neurological drug pipeline
The Edinburgh-based biotech has strengthened its intellectual property portfolio for two selective GPR17 antagonists, including its lead multiple sclerosis candidate, PTD802, which has US and UK regulatory clearance to enter clinical trials